Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

Immune checkpoint blockade (ICB) therapies can be very effective against some cancers by helping the immune system recognize cancer cells that are masquerading as healthy cells. T cells are built ...

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

and mechanisms of immune regulation. A strength of the program is the ability to translate laboratory findings into effective clinical applications. Scientists from our program have played a central ...

Patients were divided into subsets and treated with either individual blockades or combination checkpoint blockades. From these data, the researchers discovered that patients in the PD-1 blockade ...

If these preclinical results can be translated to clinical applications, it could pave the way for improved responses to immune checkpoint blockade therapies, particularly for challenging “cold ...